title: [Approaches to prevention and treatment of latex allergy].
abstract: Data on sensitization to latex as well as measures aimed at prevention and treatment of latex allergy, are presented. The intensity of the symptoms manifestation of latex allergy was shown to depend on the duration of contact with latex. To prevent the development of latex allergy, the following preparations were used: the antihistaminic preparation Claritine, the immunocorrecting preparations Ruzam and polycomponent vaccine VP-4. The use of Claritine was shown to lead to the alleviation of the symptoms of latex allergy, but after treatment with Claritine was stopped the symptoms of latex allergy reappeared. The clinical effect lasted for as long as 2 months after treatment with Ruzam, while in case of polycomponent vaccine VP-4 use remission was registered even 3 months later. The data presented thus confirm topicality of the latex allergy problem and practical importance of using the immunocorrecting preparations Ruzam and polycomponent vaccine VP-4 for its prevention and treatment.
authors.affiliation: Research Institute of Immunology, Moscow, Russia.
authors.forename: G L
authors.initials: GL
authors.lastname: Osipova
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000008:administration & dosage; D006801:Humans; D007279:Injections, Subcutaneous; D020315:Latex Hypersensitivity / Q000188:drug therapy* / Q000517:prevention & control*; D017336:Loratadine / Q000627:therapeutic use; D014611:Vaccination; D022282:Vaccines, Acellular / Q000008:administration & dosage; D017778:Vaccines, Combined / Q000008:administration & dosage
chemical_list: D018926:Anti-Allergic Agents; D001428:Bacterial Vaccines; C088865:VP-4 vaccine; D022282:Vaccines, Acellular; D017778:Vaccines, Combined; D017336:Loratadine